Nina Bhardwaj
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Nina Bhardwaj sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Nina Bhardwaj: 7 sponsored US clinical trials, none currently recruiting.
Nina Bhardwaj sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 1 trials.
Upper-quartile sponsor footprint
Nina Bhardwaj sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
7 total, page 1 of 1
Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)
NCT03241927
Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies
NCT02721043
A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
NCT02334735
Enhancement by Poly-ICLC During HIV-1 Infection
NCT02071095
Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)
NCT01984892
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
NCT01079741
Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination
NCT00821652
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 3 |
Therapeutic Areas
How the Nina Bhardwaj early-phase archive is shaped
7 indexed studies, none listed as recruiting (0% open); 5 completed (71%).
Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).
Top condition: Melanoma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Nina Bhardwaj: archived-pipeline peers nationwide
Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Nina Bhardwaj sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 archived trials
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Nina Bhardwaj page
7 registered trials is a research-attention snapshot, not an endorsement of Nina Bhardwaj or any single study.
- None of Nina Bhardwaj's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Melanoma is the condition Nina Bhardwaj studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Nina Bhardwaj pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.